Pharmacokinetic assessments
To assess the single-dose PK profile, patients took talazoparib on Day –9 of a 9-day (216 h) lead-in period; blood samples were collected at pre-dose and at 0.5, 1, 2, 4, 8, 24, 48, 96, 168, and 216 h post-dose. For the steady-state PK profile, serial samples after multiple doses of talazoparib were collected on Day 22 of the first cycle at pre-dose and at 0.5, 1, 2, 4, 8, and 24 h post-dose. Prior to serial PK sampling (Cycle 1 Day –9, Cycle 1 Day 22), patients were required to fast for at least 8 h before dosing and they had to continue fasting for 2 h after dosing to control the variability due to food effect on C